---

a) Diagnosis: Drug-Induced Parkinsonism (DIP)

• Resting tremors (pill-rolling type)
• Difficulty walking (bradykinesia, shuffling gait, rigidity)
• Dysphagia (difficulty swallowing - involvement of bulbar musculature)

---

b) Treatment

Step 1 - Reassess the antipsychotic

• If clinically possible, reduce the dose or switch to an atypical antipsychotic with lower D2-blocking potency (e.g., quetiapine, clozapine). These cause far less DIP.
• Note: Levodopa is NOT helpful if the neuroleptic drug is continued - it cannot overcome the D2 blockade and may aggravate the psychiatric disorder for which the antipsychotic was originally prescribed.
• If the antipsychotic is withdrawn, parkinsonian symptoms clear over several weeks to months. In elderly patients, this can take up to 3 months.

Step 2 - Symptomatic treatment for parkinsonism

• Anticholinergics should be withdrawn after 4-6 weeks to assess whether tolerance to the parkinsonian effects has developed. About half of patients require continued treatment.
• Even after stopping the antipsychotic, continue anticholinergic until symptoms fully resolve.

---

c) Levodopa - Mechanism of Action, Combination Therapy, and Adverse Effects

Mechanism of Action

• Benefits primarily depend on stimulation of D2 receptors (postsynaptic striatal neurons), though D1 stimulation may also contribute to maximal effect
• Levodopa is particularly effective at relieving bradykinesia and related disabilities

Importance of Combination Therapy (Levodopa + Carbidopa)

1. Reduces daily levodopa requirement by ~75% - less drug needed for the same effect
2. Plasma levels are higher and half-life longer - more drug available to reach the brain
3. Brain delivery increases from ~1-3% to ~10% of the administered dose
4. Dramatically reduces peripheral side effects - nausea/vomiting drops from ~80% to <20%; cardiac arrhythmias also reduced
5. Allows much faster titration to therapeutic doses

Adverse Effects of Levodopa

• Anorexia, nausea, vomiting in ~80% when used alone (reduced to <20% with carbidopa)
• Due to stimulation of the chemoreceptor trigger zone (CTZ) - located outside the BBB
• Management: take with food, add extra carbidopa (Lodosyn 25 mg), use domperidone or ondansetron
• Avoid phenothiazine antiemetics - they worsen parkinsonism

• Cardiac arrhythmias (tachycardia, ventricular extrasystoles, rarely atrial fibrillation) - from peripheral catecholamine formation; reduced significantly with carbidopa co-administration
• Postural hypotension - common but often asymptomatic; tends to improve with continued treatment
• Hypertension - if combined with non-selective MAO inhibitors or sympathomimetics (dangerous combination)

• Depression, anxiety, agitation, insomnia, somnolence, confusion
• Delusions, hallucinations, nightmares, euphoria
• More common when levodopa is combined with carbidopa (more drug reaches the brain)
• Managed with atypical antipsychotics (quetiapine, clozapine) or pimavanserin (5-HT2A inverse agonist) for Parkinson psychosis

• Choreiform, athetoid, or dystonic movements - most common long-term complication
• Particularly affects the face, mouth, tongue, and limbs
• Related to peak plasma levodopa levels; managed by dose reduction or adding amantadine

• "Wearing-off" effect - symptom recurrence before next dose as plasma levodopa falls
• "On-off" phenomenon - unpredictable sudden shifts between mobility (on) and immobility (off), unrelated to dosing schedule
• Managed with: extended-release carbidopa/levodopa (Rytary), COMT inhibitors (entacapone, opicapone), MAO-B inhibitors (rasagiline), or deep brain stimulation

• Darkening of urine (levodopa metabolites - not harmful)
• Rarely, neuroleptic malignant-like syndrome on abrupt withdrawal

---

Summary Table

---

Neurohumoral Transmission

---

1. Historical Background and Evidence

1. The physiologically active compound and its biosynthetic enzymes are present at appropriate anatomical sites
2. The compound can be recovered from perfusate of an innervated structure during nerve stimulation but not at rest
3. The compound produces responses identical to nerve stimulation when administered exogenously
4. Responses to nerve stimulation and the administered compound are modified identically by pharmacological antagonists

Note: Nitric oxide (NO) is an exception - it is a neurotransmitter in some postganglionic parasympathetic nerves but is synthesized on demand rather than stored and released by exocytosis.

---

2. Steps in Neurohumoral Transmission

Step 1 - Axonal Conduction

• At rest: interior is ~70 mV negative relative to exterior (resting membrane potential)
• Depolarization to threshold opens voltage-sensitive Na+ channels → rapid Na+ influx → depolarization with positive overshoot
• Followed by K+ efflux → repolarization
• Local circuit currents propagate the AP along the axon in a forward direction
• The depolarized region enters a brief refractory state to ensure unidirectional propagation

---

Step 2 - Junctional (Synaptic) Transmission

a) Storage and Release of Transmitter

• Non-peptide neurotransmitters (biogenic amines) are synthesized in axonal terminals and stored in synaptic vesicles
• Vesicular storage is driven by a vesicular proton pump (vesicular ATPase)
• Synaptic vesicle proteins include: synapsin, synaptophysin, synaptogyrin
• The exocytosis machinery involves SNARE proteins: synaptobrevin (vesicular membrane), SNAP-25 and syntaxin (plasma membrane), and synaptotagmin (Ca²+ sensor)

1. Docking - Munc18 binds syntaxin, stabilizing the SNARE complex
2. Priming I - Syntaxin assembles with SNAP-25, allowing synaptobrevin to bind
3. Priming II - Complexin binds the SNARE complex; synaptotagmin binds Ca²+
4. Fusion - Ca²+ entry triggers full membrane fusion and exocytosis
5. Reset - NSF ATPase and SNAP adapters dissociate the SNARE complex

Botulinum toxin cleaves SNARE proteins (synaptobrevin) and blocks ACh release at the NMJ. Tetanus toxin acts similarly on inhibitory neurons in the CNS.

b) Combination with Postjunctional Receptor

• Released transmitter binds specific receptors on the postsynaptic membrane
• Ionotropic receptors (ligand-gated ion channels): rapid - opens within milliseconds
  • Excitatory: nicotinic, glutamate, 5-HT3 → Na+ influx → EPSP (depolarization)
  • Inhibitory: GABA, glycine → Cl- influx → IPSP (hyperpolarization)
• Metabotropic receptors (G protein-coupled): slower, via second messengers
  • E.g., muscarinic receptors, α and β adrenergic receptors
  • Signal through cAMP (adenylyl cyclase), IP3/DAG (phospholipase C), or modulation of K+/Ca²+ channels

c) Initiation of Response

• Summation of microscopic channel-opening events generates the excitatory postsynaptic potential (EPSP)
• Sufficient depolarization triggers a new action potential in the postjunctional cell

d) Termination of Transmitter Action

• Enzymatic hydrolysis (e.g., ACh by acetylcholinesterase)
• Reuptake into the nerve terminal (primary for catecholamines)
• Diffusion away from the synapse

e) Non-electrogenic (Trophic) Functions

• Neurotransmitters also control enzyme turnover, receptor density, and synaptic plasticity through trophic actions

---

3. Cholinergic Transmission

Synthesis of Acetylcholine (ACh)

• Choline acetyltransferase (ChAT) catalyzes: Choline + Acetyl CoA → ACh
• Rate-limiting step = uptake of choline via high-affinity choline transporter (CHT1) from the extracellular fluid (Na+-dependent)
• Blocked by: hemicholinium
• Choline is recycled after ACh hydrolysis
• ACh is packaged into vesicles by vesicular ACh transporter (VAChT)
• Blocked by: vesamicol

Release of ACh

• Action potential → Ca²+ entry via voltage-gated Ca²+ channels → SNARE-mediated exocytosis
• Two pools: readily releasable pool (near membrane, newly synthesized) and reserve pool (replenishes the first)

Degradation of ACh

• Acetylcholinesterase (AChE) hydrolyzes ACh → choline + acetate (within <1 millisecond at the NMJ)
• Choline is recycled back into the terminal
• Butyrylcholinesterase (pseudocholinesterase) - found in liver/plasma; physiologically hydrolyzes ingested plant esters

Cholinergic Receptors

---

4. Adrenergic (Catecholamine) Transmission

Synthesis of Norepinephrine (NE)

1. Tyrosine → DOPA by tyrosine hydroxylase (TH) [rate-limiting step; cofactor: tetrahydrobiopterin]
2. DOPA → Dopamine by aromatic L-amino acid decarboxylase (dopa decarboxylase) [cofactor: pyridoxal phosphate]
3. Dopamine → Norepinephrine by dopamine β-hydroxylase (DβH) [cofactor: ascorbate] - inside storage vesicles
4. Norepinephrine → Epinephrine by phenylethanolamine-N-methyltransferase (PNMT) [cofactor: S-adenosylmethionine] - only in adrenal medulla and a few brainstem neurons

Release of NE

• Action potential → Ca²+ entry → exocytosis of vesicular contents (NE, ATP, NPY, chromogranins, DβH)
• SNARE proteins (SNAP-25, syntaxin, synaptobrevin) mediate fusion

Termination of NE Action

• MAO (monoamine oxidase) - intraneuronally; MAO-B selective for DA and phenylethylamines; MAO-A selective for 5-HT and NE
• COMT (catechol-O-methyltransferase) - extraneuronally

Adrenergic Receptors

---

5. Summary of Key Neurotransmitter Systems

---

Diagnosis: Hypovolemic Shock (Hemorrhagic Shock)

• Rapid (tachycardic) pulse - compensatory response to falling cardiac output
• Cold, clammy, cyanotic skin - cutaneous vasoconstriction shunting blood to vital organs
• Tachypnea - compensatory hyperventilation to improve oxygenation and blow off CO2
• Unconsciousness - end-organ (brain) hypoperfusion

---

Classification of Shock

---

Pathogenesis of Shock

Core Mechanism

Massive hemorrhage → ↓ circulating blood volume → ↓ venous return → ↓ cardiac output → ↓ tissue perfusion → cellular hypoxia → organ dysfunction → death (if uncorrected)

Compensatory (Neurohumoral) Responses Activated

1. Baroreceptor reflexes - carotid/aortic baroreceptors detect falling BP → reflex sympathetic activation
2. Catecholamine release (epinephrine from adrenal medulla, NE from sympathetics) → tachycardia, peripheral vasoconstriction
3. Renin-Angiotensin-Aldosterone System (RAAS) activation → angiotensin II causes vasoconstriction; aldosterone promotes renal Na+ and water retention
4. ADH (vasopressin) release from posterior pituitary → water reabsorption by kidney
5. Generalized sympathetic stimulation → redistributes blood away from skin, gut, and kidneys toward heart and brain

• Tachycardia
• Peripheral vasoconstriction (cold, clammy, pale/cyanotic skin)
• Oliguria (urine output falls)
• Relative preservation of cardiac and cerebral perfusion initially

---

Evolution (Stages) of Shock

Stage 1 - Nonprogressive (Compensated) Stage

• Reflex compensatory mechanisms are fully activated
• Vital organ (heart, brain) perfusion is maintained
• Clinically: tachycardia, tachypnea, cool clammy skin, mild anxiety
• Cellular injury is reversible at this stage
• Blood is shunted away from skin/gut to heart and brain
• Cutaneous vasoconstriction accounts for the cold, clammy, cyanotic appearance

Stage 2 - Progressive Stage

• Underlying cause is not corrected → widespread tissue hypoxia develops
• Aerobic respiration fails → anaerobic glycolysis → lactic acid production → metabolic lactic acidosis
• Lactic acidosis lowers tissue pH → vasomotor response is blunted
• Arterioles dilate → blood pools in the microcirculation
• Peripheral pooling worsens cardiac output (vicious cycle)
• Endothelial anoxic injury → risk of Disseminated Intravascular Coagulation (DIC)
• Vital organs (heart, brain, kidney) begin to fail
• Clinically: worsening hypotension, deepening coma, oliguria/anuria, worsening lactic acidosis

Stage 3 - Irreversible Stage

• Severe, sustained tissue injury → widespread cell death
• Lysosomal enzyme leakage from necrotic cells further worsens the shock state (autolytic injury)
• Myocardial contractile function deteriorates (partly from excess NO synthesis reducing cardiac muscle tone)
• Ischemic bowel allows gut bacteria to enter the circulation → superimposed bacteremic shock (septic shock on top of hemorrhagic shock)
• Acute tubular necrosis (ATN) of kidneys from sustained ischemia → acute renal failure
• Despite heroic therapeutic efforts, death is inevitable once this stage is reached
• The terminal pathway is multi-organ failure (MOF)

---

Morphology of Shock

1. Brain

• Ischemic encephalopathy - neuronal necrosis in the most vulnerable areas: hippocampus (Sommer's sector), cerebellar Purkinje cells, and neocortical neurons
• Watershed (border-zone) infarcts in areas between the end-territories of major cerebral arteries (ACA-MCA and MCA-PCA junction zones)
• Neurons are the most sensitive cells to hypoxia - irreversible damage after just 3-5 minutes of complete anoxia

2. Heart

• Subendocardial hemorrhage and necrosis - the subendocardial myocardium is the zone most vulnerable to ischemia (farthest from coronary supply, highest oxygen demand)
• Focal areas of myocardial necrosis (contraction band necrosis) - seen in hemorrhagic shock
• Reduced myocardial contractility with worsening shock (partly mediated by TNF, IL-1, and NO in later stages)

3. Kidneys

• Acute Tubular Necrosis (ATN) - the most characteristic morphological finding
  • Patchy ischemic necrosis of tubular epithelium, especially the proximal tubule and thick ascending limb of Henle
  • Tubular casts (pigmented) in the distal tubules and collecting ducts
  • Interstitial edema
  • Intact tubular basement membrane (important - allows regeneration if patient survives)
• Clinically: oliguria, rising BUN and creatinine, electrolyte disturbances
• Prognosis: tubular cells can regenerate - reversible if perfusion is restored

4. Lungs

• Lungs are relatively resistant to hypoxic injury in pure hemorrhagic shock
• However, when shock is complicated by trauma or sepsis: Diffuse Alveolar Damage (DAD) develops
  • Interstitial and alveolar edema
  • Hyaline membrane formation (protein-rich exudate)
  • Type II pneumocyte hyperplasia
  • This is the pathological substrate of "Shock Lung" = Acute Respiratory Distress Syndrome (ARDS)
• Clinically: hypoxia, bilateral infiltrates on CXR, respiratory failure

5. Adrenal Glands

• Cortical cell lipid depletion - a non-specific stress response reflecting increased use of stored cholesterol/lipids for cortisol synthesis
• In severe septic shock complicated by DIC: adrenal hemorrhage → Waterhouse-Friderichsen syndrome → adrenal insufficiency
• Loss of cortisol in late stages contributes to hemodynamic collapse

6. Gastrointestinal Tract

• Mucosal ischemia → stress ulcers (Curling's ulcers in the stomach/duodenum)
• Mucosal barrier breakdown → bacterial translocation (gut bacteria enter the bloodstream)
• This is a key mechanism for converting hypovolemic shock into septic shock in the later stages
• Can also develop hemorrhagic gastroenteritis and ischemic colitis

7. Liver

• Centrilobular necrosis (zone 3 of hepatic acinus - most distal from hepatic artery supply, most sensitive to hypoxia)
• "Nutmeg liver" appearance grossly (congested, red-yellow mottled)
• Rising liver enzymes (transaminases) → jaundice in severe/prolonged shock

---

Summary Flowchart

RTA → Hemorrhage
        ↓
  ↓ Circulating Blood Volume
        ↓
  ↓ Cardiac Output
        ↓
  ↓ Tissue Perfusion
        ↓
┌──────────────────────────────────────────┐
│  COMPENSATORY STAGE                       │
│  ↑ HR, ↑ Catecholamines, ↑ RAAS, ↑ ADH  │
│  Peripheral vasoconstriction              │
│  Cold clammy cyanotic skin                │
└──────────────────────────────────────────┘
        ↓ (if not corrected)
┌──────────────────────────────────────────┐
│  PROGRESSIVE STAGE                        │
│  Anaerobic glycolysis → Lactic acidosis   │
│  Arteriolar dilation → Microvascular      │
│  pooling → DIC risk                       │
│  Vital organ dysfunction begins           │
└──────────────────────────────────────────┘
        ↓ (if not corrected)
┌──────────────────────────────────────────┐
│  IRREVERSIBLE STAGE                       │
│  Lysosomal rupture, ↓ myocardial         │
│  contractility, gut translocation,        │
│  ATN, ARDS, MOF → DEATH                  │
└──────────────────────────────────────────┘

---

Clinical Note

Prognosis: More than 90% of young, otherwise healthy patients with hypovolemic shock survive with appropriate management (aggressive IV fluid resuscitation, blood transfusion, surgical hemorrhage control). This compares favorably with cardiogenic or septic shock, which carry substantially worse outcomes even with state-of-the-art care. The key is rapid intervention before the irreversible stage is reached.

---

Diagnosis

Primary Diagnosis: Drug-Induced Agranulocytosis

• Neutropenia = ANC < 1500/mm³
• Severe neutropenia = ANC < 500/mm³
• Agranulocytosis = ANC < 100-500/mm³ (marked reduction, near absence of neutrophils)

---

Classification of Neutropenia/Agranulocytosis

Broad Mechanism-Based Classification

AGRANULOCYTOSIS
├── A. Decreased Production (Inadequate/Ineffective Granulopoiesis)
│     ├── 1. Suppression of Hematopoietic Stem Cells (HSCs)
│     │     ├── Aplastic anemia
│     │     ├── Marrow infiltration (leukemia, granulomas, tumors)
│     │     └── Myelotoxic chemotherapy (affects all cell lines)
│     ├── 2. Suppression of Committed Granulocytic Precursors
│     │     └── Drug toxicity (selective - other lineages spared)
│     ├── 3. Ineffective Hematopoiesis
│     │     ├── Megaloblastic anemia (B12/folate deficiency)
│     │     └── Myelodysplastic neoplasms
│     └── 4. Congenital
│           └── Kostmann syndrome (severe congenital neutropenia)
│
└── B. Increased Destruction/Sequestration
      ├── 1. Immune-mediated neutrophil destruction (drug-induced or idiopathic)
      ├── 2. Splenomegaly (splenic sequestration)
      ├── 3. Overwhelming infection (bacterial, fungal, rickettsial)
      └── 4. LGL leukemia (CD8+ cytotoxic T cell suppression of myelopoiesis)

Drug-Based Classification of Causes

---

Pathogenesis

---

Mechanism 1: Direct Toxic/Myelosuppressive Effect

Drug enters bone marrow
        ↓
Direct toxic effect on granulocytic precursors
(myeloblasts, promyelocytes, myelocytes)
        ↓
Selective destruction of granulocyte precursors
(erythroid and megakaryocytic lineages spared)
        ↓
Maturation arrest at promyelocyte/myelocyte stage
        ↓
↓↓ Release of mature neutrophils into blood
        ↓
Agranulocytosis

---

Mechanism 2: Immune-Mediated (Hapten) Mechanism

STEP 1: SENSITIZATION PHASE
Drug (hapten) binds to neutrophil surface proteins
→ Forms drug-protein complex (neoantigen)
→ Presented to immune system as foreign antigen
→ Antibody production against drug-neutrophil complex
(IgG/IgM anti-neutrophil antibodies generated)

STEP 2: SUBSEQUENT EXPOSURE
Re-exposure to the same drug
        ↓
Drug binds to neutrophil surface again
        ↓
Pre-formed antibodies (IgG) attach to drug-neutrophil complex
        ↓
Two pathways of destruction:
  ├─ COMPLEMENT ACTIVATION (IgM/IgG):
  │   Complement fixed on neutrophil surface
  │   → Membrane Attack Complex (MAC)
  │   → Direct neutrophil lysis in circulation
  │
  └─ OPSONIZATION + PHAGOCYTOSIS (IgG):
      Fc receptors on macrophages/monocytes
      recognize IgG-coated neutrophils
      → Phagocytosis in spleen and liver
      → Peripheral neutrophil destruction
        ↓
Rapid fall in circulating neutrophils
        ↓
AGRANULOCYTOSIS

Additional Immune Mechanism: Autoimmune Neutropenia

• Antibodies directed against neutrophil surface antigens
• Idiopathic or associated with SLE, rheumatoid arthritis (Felty syndrome)
• Neutrophils opsonized → destroyed in spleen

---

Morphology

Bone Marrow Changes

Peripheral Blood

• Near-absent neutrophils (ANC <500)
• Other cell lines (RBCs, platelets, lymphocytes) relatively preserved in pure drug-induced cases

Sites of Infection (Consequences of Agranulocytosis)

• Oral cavity most characteristic: Necrotizing ulcerative lesions of the gingiva, floor of mouth, buccal mucosa, and pharynx
  • Deep, undermined ulcers covered by gray-to-green-black necrotic membranes
  • Masses of bacteria/fungi visible histologically with minimal leukocytic inflammatory response (no neutrophils available)
• Lungs, urinary tract, kidneys: Severe invasive bacterial or fungal infections
• Deep fungal infections: Candida and Aspergillus (characteristically opportunistic)
• All sites share the hallmark: massive microbial growth with absent neutrophilic infiltrate

---

Clinical Features and Danger Threshold

• Malaise, chills, high-grade fever (often the first sign)
• Oropharyngeal ulcers/mucositis
• Weakness and fatigue
• If untreated: rapidly progressive sepsis → death

---

Management Principles

1. Stop the offending drug immediately (causative antibiotic)
2. Broad-spectrum antibiotics at first sign of infection (do not wait for culture results - infections are fulminant)
3. G-CSF (Granulocyte Colony-Stimulating Factor / Filgrastim) - stimulates granulocyte production from marrow precursors, accelerates recovery
4. Reverse isolation (protective environment to minimize infection exposure)
5. Bone marrow biopsy to assess cellularity and mechanism
6. Antifungal prophylaxis (fluconazole/voriconazole) given risk of Candida/Aspergillus

Prognosis: With early diagnosis, cessation of the offending drug, and G-CSF therapy, most patients recover. Mortality is high if diagnosis is delayed and fulminant sepsis develops.

---

a) Clinical Condition: Gas Gangrene (Clostridial Myonecrosis)

---

b) Etiological Agent

Primary Agent: Clostridium perfringens (also called C. welchii)

Other Clostridial Species Causing Gas Gangrene:

• Clostridium septicum
• Clostridium novyi (Type A)
• Clostridium sordellii
• Clostridium bifermentans
• Clostridium histolyticum
• Clostridium sporogenes

Note: Non-clostridial gas-producing organisms (coliforms, mixed aerobic/anaerobic bacteria) are found in 60-85% of gas gangrene cases as co-infectors.

Types of Clostridial Wound Infection:

---

c) Pathogenesis and Clinical Manifestations

Pathogenesis

Step 1 - Setting the Stage (Prerequisite Conditions)

Crush injury + Soil contamination
        ↓
Clostridial spores introduced into wound
        ↓
Crushed/devitalized tissue → disrupted blood supply
        ↓
Reduced tissue oxygen tension (low redox potential)
        ↓
Anaerobic microenvironment created
        ↓
Spores GERMINATE into vegetative (actively dividing) form

• Devitalized (dead/ischemic) muscle tissue
• Soil contamination
• Retained foreign bodies
• Delayed wound treatment / wound closure without debridement
• Immunosuppression, diabetes, peripheral vascular disease

Step 2 - Toxin Production (Core Mechanism)

• It is a phospholipase C that hydrolyzes lecithin (phosphatidylcholine) - a major component of all cell membranes
• This directly disrupts membrane integrity of red blood cells (hemolysis), platelets (thrombocytopenia), neutrophils (immune evasion), and muscle cells (myonecrosis)
• Also causes widespread capillary damage and microvascular thrombosis

Step 3 - Vicious Cycle of Tissue Destruction

Alpha-toxin → destroys muscle cell membranes
        ↓
Muscle necrosis + capillary thrombosis
        ↓
Further tissue ischemia → deeper anaerobic conditions
        ↓
More bacterial growth + more toxin production
        ↓
Spreading necrosis along muscle planes
        ↓
Gas production (H₂S + CO₂) from fermentation
→ spreads along fascial planes → CREPITUS
        ↓
Systemic absorption of toxins
        ↓
Hemolysis → hemolytic anemia + hemoglobinuria
Thrombocytopenia → coagulopathy
Myocardial suppression (theta toxin) → cardiogenic shock
        ↓
MULTI-ORGAN FAILURE → DEATH (if untreated)

Clinical Manifestations

Without treatment: 100% fatal. Death usually occurs from septic shock, renal failure, and cardiovascular collapse within 48-72 hours of established infection.

---

d) Laboratory Diagnosis and Treatment

Laboratory Diagnosis

I. Microscopy (Most Rapid and Clinically Useful)

• Large, rectangular Gram-positive bacilli ("boxcar" shaped)
• Paucity or complete absence of polymorphonuclear leukocytes (neutrophils)
  • This is a hallmark finding - the toxins destroy neutrophils, so no inflammatory response is seen
• May see Gram-negative bacilli as co-infectors

II. Culture (Confirmatory)

• Grows rapidly (generation time ~8 minutes - fastest of all pathogens)
• Non-motile (unlike other clostridia)
• Produces lecithinase (alpha-toxin) - detected by Nagler reaction
• Ferments lactose, glucose, maltose, sucrose with acid and gas
• Does NOT ferment mannitol

III. Imaging Studies

• Plain X-ray of the limb: Gas shadows (feathery pattern) tracking along muscle planes between fascial layers - highly characteristic
• CT scan / MRI: More sensitive for detecting early gas in deep tissue planes, especially in chest and abdominal involvement
• Gas in soft tissue is non-specific but very suggestive in the clinical context

IV. Blood Investigations

V. Histopathology (if tissue biopsied)

• Extensive myonecrosis with coagulative necrosis of muscle fibers
• Ghost-like muscle cells with no nuclei
• Massive bacterial colonies
• Absent or minimal neutrophilic infiltrate (toxins destroy neutrophils)
• Gas bubbles within tissue

---

Treatment

1. Resuscitation and ICU Monitoring

• IV access + aggressive IV fluid resuscitation
• Close monitoring: hemolysis, renal function, cardiac function
• Correct anemia (blood transfusion), coagulopathy (FFP, platelets)
• Endotracheal intubation for respiratory compromise
• Vasopressors if septic shock

2. Surgical Treatment (PRIMARY and Most Important)

3. Antibiotic Therapy

The combination of penicillin G + clindamycin is the treatment of choice. Clindamycin's ability to inhibit toxin synthesis is its critical advantage in this setting.

4. Hyperbaric Oxygen Therapy (HBO)

5. Antitoxin

• Polyvalent gas gangrene antitoxin is available but its role is limited - passive immunity from antitoxin may help neutralize circulating toxin
• Not routinely recommended in current guidelines; surgical removal of source is paramount

Summary of Treatment Approach

EMERGENCY MEASURES
│
├─ ICU admission + monitoring
├─ IV fluids + hemodynamic support
│
├─ SURGERY (IMMEDIATE - do not delay)
│   ├─ Wound opening and exploration
│   ├─ Radical debridement of all necrotic tissue
│   ├─ Fasciotomy if needed
│   └─ Amputation if life-threatening systemic toxicity
│
├─ ANTIBIOTICS (START IMMEDIATELY)
│   └─ Penicillin G + Clindamycin IV
│
└─ HYPERBARIC OXYGEN
    └─ 3.0 ATA × 90 min, 3x/day × day 1, then 2x/day × 2-5 days

Prognosis

---

Anti-Tuberculosis Drugs

---

Classification

First-Line Drugs (RIPE mnemonic)

Second-Line Drugs

---

Standard Treatment Regimens

Traditional 6-Month Regimen (Drug-susceptible TB)

Mnemonic: "2 RIPE → 4 RI"

Newer 4-Month Regimen

• Intensive phase (8 weeks): Rifapentine + Moxifloxacin + INH + PZA
• Continuation phase (9 weeks): Rifapentine + Moxifloxacin + INH
• Non-inferior to 6-month regimen for drug-susceptible pulmonary TB in persons ≥12 years weighing ≥40 kg

---

First-Line Drugs: Detailed Profile

---

1. Isoniazid (INH)

• INH is a prodrug - activated by KatG (mycobacterial catalase-peroxidase enzyme)
• The activated form forms a covalent complex with AcpM (acyl carrier protein) and KasA (β-ketoacyl carrier protein synthetase)
• This blocks mycolic acid synthesis - mycolic acids are unique, long-chain fatty acids essential for the mycobacterial cell wall
• Result: disruption of cell wall integrity → bactericidal effect
• Active against both extracellular and intracellular organisms (penetrates macrophages)
• Bactericidal for actively growing tubercle bacilli; bacteriostatic for dormant organisms

• Mutation/deletion of katG gene → cannot activate INH → high-level resistance
• Overexpression of inhA (NADH-dependent acyl carrier protein reductase) → low-level resistance + cross-resistance to ethionamide
• Mutations in ksaA gene

• Well absorbed orally (best on empty stomach; fatty meals reduce peak by 50%)
• Widely distributed in all tissues and body fluids including CSF (20-100% of serum levels)
• Metabolized in liver by N-acetyltransferase (NAT2) - acetylation
• Genetic polymorphism in acetylation:
  • Slow acetylators - higher plasma levels, longer half-life (~3 hours), more prone to toxicity (neuropathy, hepatitis)
  • Rapid acetylators - lower plasma levels, shorter half-life (<1 hour), may need higher doses with intermittent therapy
• Excreted in urine; no dose adjustment needed in renal failure
• Inhibits CYP450 enzymes → ↑ phenytoin, carbamazepine, benzodiazepine levels

---

2. Rifampicin (Rifampin)

• Inhibits bacterial DNA-dependent RNA polymerase by binding to its β-subunit (rpoB gene product)
• Blocks the initiation step of RNA transcription → prevents mRNA synthesis
• Bactericidal for mycobacteria
• Human RNA polymerase does NOT bind rifampin - basis for selective toxicity
• Kills organisms in all locations: extracellular, intracellular (within macrophages), in abscess walls, in lung cavities - unique advantage

• Point mutations in rpoB gene → reduced binding of rifampin to RNA polymerase
• Resistance emerges rapidly if used as a single agent (1 in 10⁶ organisms are naturally resistant)
• Cross-resistance to all rifamycins (rifabutin, rifapentine)

• Well absorbed orally; take on empty stomach
• Excreted mainly via bile (enterohepatic circulation); small amount in urine
• Excreted as deacetylated metabolite in feces
• Penetrates widely into tissues including CSF, abscesses, and cells

Rifampin + INH/PZA together have additive hepatotoxicity risk.

---

3. Pyrazinamide (PZA)

• A nicotinamide analog (prodrug)
• Taken up by macrophages; converted inside the acidic lysosomal environment by mycobacterial pyrazinamidase (pncA gene product) into pyrazinoic acid - the active form
• Pyrazinoic acid disrupts mycobacterial cell membrane metabolism and transport functions
• Unique activity: kills organisms residing within the ACIDIC environment of macrophage lysosomes (pH 5.5) - other drugs are inactive here
• This is why PZA is the critical "sterilizing agent" in short-course regimens - eliminates the last reservoir of dormant intracellular bacilli that can cause relapse
• Inactive at neutral pH

• Impaired uptake of PZA
• Mutations in pncA gene → impaired conversion to pyrazinoic acid
• No cross-resistance with INH or other drugs

• Well absorbed orally; widely distributed including inflamed meninges
• Half-life: 8-11 hours
• Metabolized by liver; metabolites renally cleared
• Reduce frequency (not dose) in renal failure (CrCl <30 mL/min: thrice weekly dosing)

---

4. Ethambutol (EMB)

• Inhibits arabinosyl transferase (embB gene product)
• This enzyme is responsible for the synthesis of arabinogalactan - a key cell wall polysaccharide that links the peptidoglycan core to the mycolic acid outer layer
• Disrupts mycobacterial cell wall synthesis
• Primarily bacteriostatic at standard doses; bactericidal at high doses
• Active against M. tuberculosis and M. kansasii

• Mutations in embB gene (codon 306 mutation most common)

• Well absorbed orally
• Widely distributed; penetrates CSF only when meninges are inflamed
• Excreted mainly in urine (dose adjustment needed in renal failure)

Contraindicated in young children and infants who cannot be tested for visual changes.

---

5. Streptomycin (S)

• Aminoglycoside antibiotic
• Binds irreversibly to 30S ribosomal subunit (16S rRNA)
• Inhibits protein synthesis by:
  1. Blocking initiation of translation
  2. Causing misreading of mRNA codons → incorporation of wrong amino acids
• Bactericidal
• Active only against extracellular bacilli (does NOT penetrate cells well)
• Does NOT penetrate CSF well (even with inflamed meninges)

• Not absorbed orally - given by IM or IV injection
• Renally excreted; dose adjustment essential in renal failure
• Ototoxic - auditory and vestibular damage (monitor audiometry)

Contraindicated in pregnancy (causes fetal sensorineural deafness - vestibulotoxic to fetus)

---

Second-Line Drugs: Key Agents

Fluoroquinolones (Moxifloxacin, Levofloxacin)

• Inhibit DNA gyrase (topoisomerase II) and topoisomerase IV
• Moxifloxacin is the most active against M. tuberculosis
• Now incorporated into first-line 4-month regimen
• Used in MDR-TB regimens
• Adverse effects: QT prolongation (moxifloxacin), tendinopathy, CNS effects

Bedaquiline

• Novel mechanism - first new TB drug approved since 1971 (FDA 2012)
• Inhibits mycobacterial ATP synthase (F₀ subunit) → blocks energy production
• Active against both replicating and non-replicating bacilli
• Key drug in MDR-TB and XDR-TB regimens
• Used with linezolid + pretomanid for XDR-TB (BPaL regimen)
• Adverse effects: QT prolongation (ECG monitoring required), hepatotoxicity, nausea

Linezolid

• Oxazolidinone antibiotic
• Inhibits 50S ribosomal subunit (23S rRNA) → blocks protein synthesis
• Used in MDR-TB and XDR-TB (BPaL regimen: Bedaquiline + Pretomanid + Linezolid)
• Adverse effects: bone marrow suppression (anemia, thrombocytopenia), irreversible peripheral and optic neuropathy with prolonged use; serotonin syndrome risk

Ethionamide

• Structural analog of INH; also inhibits mycolic acid synthesis (via inhA)
• Cross-resistance with low-level INH resistance (inhA mutations)
• Adverse effects: severe GI intolerance (nausea, vomiting - dose-limiting), hepatotoxicity, neurotoxicity, hypothyroidism (with prolonged use)

Cycloserine

• Inhibits D-alanine racemase and D-Ala-D-Ala ligase → blocks peptidoglycan cell wall synthesis
• Adverse effects: CNS toxicity - anxiety, depression, psychosis, seizures (major limiting factor; use pyridoxine supplementation)

Para-Aminosalicylic Acid (PAS)

• Competitive inhibitor of folate synthesis (similar to sulfonamides) in mycobacteria
• Bacteriostatic
• Adverse effects: GI intolerance (severe nausea/vomiting), hypersensitivity syndrome, hypothyroidism (long-term)

Rifabutin

• Rifamycin derivative; similar mechanism to rifampin (rpoB binding)
• Less potent CYP450 inducer than rifampin → preferred over rifampin in HIV patients on antiretroviral therapy (protease inhibitors, NNRTIs)
• Adverse effects: similar to rifampin + leukopenia, thrombocytopenia, optic neuritis, orange body fluid discoloration

---

Comparative Summary Table

---

MDR-TB and XDR-TB

---

Key Principle: Why Combination Therapy?

---

Treatment of Hypertension - Pharmacology

---

Classification of Antihypertensive Drugs

I.   DIURETICS
     A. Thiazides - Hydrochlorothiazide, Chlorthalidone, Indapamide
     B. Loop diuretics - Furosemide, Bumetanide, Torsemide
     C. Potassium-sparing - Spironolactone, Eplerenone, Amiloride, Triamterene

II.  RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (RAAS) BLOCKERS
     A. ACE Inhibitors (ACEIs) - Captopril, Enalapril, Lisinopril, Ramipril
     B. Angiotensin Receptor Blockers (ARBs) - Losartan, Valsartan, Candesartan
     C. Direct Renin Inhibitor - Aliskiren
     D. Aldosterone Antagonists - Spironolactone, Eplerenone (MRAs)

III. CALCIUM CHANNEL BLOCKERS (CCBs)
     A. Dihydropyridines - Amlodipine, Nifedipine, Felodipine, Nicardipine
     B. Non-dihydropyridines - Verapamil (phenylalkylamine), Diltiazem (benzothiazepine)

IV.  DRUGS ACTING ON SYMPATHETIC NERVOUS SYSTEM
     A. Beta-blockers
        1. Non-selective - Propranolol, Nadolol
        2. Cardioselective (β1) - Metoprolol, Atenolol, Bisoprolol
        3. With α-blocking - Labetalol, Carvedilol
     B. Alpha-1 blockers - Prazosin, Doxazosin, Terazosin
     C. Central sympatholytics - Clonidine, Methyldopa
     D. Adrenergic neuron blockers - Guanethidine (historical)
     E. Ganglion blockers - Mecamylamine (historical)

V.   VASODILATORS
     A. Arteriolar - Hydralazine, Minoxidil, Diazoxide
     B. Arteriovenous - Sodium Nitroprusside (parenteral)

VI.  NEWER/OTHER AGENTS
     - Sacubitril/Valsartan (ARNi), Azilsartan, Olmesartan

---

I. Diuretics

A. Thiazide Diuretics

• Inhibit the Na⁺-Cl⁻ co-transporter (NCC) in the distal convoluted tubule → ↑ Na⁺ and water excretion
• Acutely: ↓ blood volume → ↓ cardiac output → ↓ BP
• Chronically (6-8 weeks): cardiac output normalizes, but peripheral vascular resistance decreases (primary sustained mechanism - related to reduced intracellular Ca²⁺ in vessel walls from altered Na⁺-Ca²⁺ exchange)
• Effective in lowering BP by 10-15 mmHg as monotherapy

B. Loop Diuretics

C. Potassium-Sparing Diuretics / Aldosterone Antagonists

• Spironolactone/Eplerenone: block mineralocorticoid (aldosterone) receptors → prevent Na⁺ retention and K⁺ loss
• Amiloride/Triamterene: block epithelial Na⁺ channels (ENaC) in collecting duct

---

II. Renin-Angiotensin-Aldosterone System (RAAS) Blockers

A. ACE Inhibitors (ACEIs)

• Block Angiotensin-Converting Enzyme (ACE/kininase II) which normally:
  • Converts Angiotensin I → Angiotensin II (a potent vasoconstrictor + aldosterone stimulator)
  • Degrades bradykinin (a vasodilator)
• Net effects: ↓ Angiotensin II → ↓ peripheral vascular resistance + ↓ aldosterone → ↓ Na⁺ retention
• Accumulation of bradykinin → additional vasodilation (but also causes cough and angioedema)
• No reflex tachycardia (unique advantage vs. direct vasodilators) - due to baroreceptor resetting and enhanced parasympathetic tone

• Most are prodrugs (enalapril → enalaprilat; lisinopril is active as given)
• Most excreted renally (reduce dose in renal failure except fosinopril, moexipril)
• Captopril: short-acting, requires 2-3x/day dosing; rest can be given once daily

• Diabetic nephropathy: Reduce glomerular efferent arteriolar resistance → ↓ intraglomerular pressure → reduce proteinuria and slow CKD progression (first-line even without hypertension in diabetics)
• Post-MI: Reduce mortality and prevent cardiac remodeling
• Heart failure: Cornerstone of management (↓ preload and afterload)
• Left ventricular hypertrophy: Regression of LVH

B. Angiotensin Receptor Blockers (ARBs)

• Block AT₁ receptors (Angiotensin II type 1) → prevent all actions of Angiotensin II
• Do NOT affect bradykinin → no cough or angioedema (major advantage over ACEIs)
• Same cardiovascular and renal protective benefits as ACEIs

Note: ACEIs and ARBs should NOT be combined - dual RAAS blockade increases adverse effects without additive benefit.

C. Direct Renin Inhibitor

---

III. Calcium Channel Blockers (CCBs)

• Block voltage-gated L-type Ca²⁺ channels in vascular smooth muscle and cardiac cells
• In vascular smooth muscle: ↓ Ca²⁺ entry → vasodilation → ↓ peripheral vascular resistance → ↓ BP
• Different drugs have different selectivity:

• Elderly patients (safe and effective)
• Isolated systolic hypertension
• Angina pectoris (dihydropyridines + non-DHPs)
• Vasospastic (Prinzmetal's) angina
• Atherosclerosis (CCBs preferred)
• Raynaud's phenomenon

---

IV. Drugs Acting on the Sympathetic Nervous System

A. Beta-Adrenoceptor Blockers (β-Blockers)

• Non-selective (β1+β2): Propranolol, Nadolol, Timolol
• Cardioselective (β1 > β2): Metoprolol, Atenolol, Bisoprolol, Nebivolol
• Mixed α+β: Labetalol, Carvedilol

1. ↓ Cardiac output via β1 blockade (↓ HR and contractility)
2. ↓ Renin release from juxtaglomerular cells (β1 mediated) → ↓ RAAS activation → ↓ Angiotensin II
3. Central sympatholytic effect (reduced CNS sympathetic outflow)
4. Peripheral presynaptic β blockade → ↓ NE release

• Post-MI (reduce mortality)
• Heart failure (metoprolol, bisoprolol, carvedilol - reduce mortality)
• Angina pectoris
• Aortic dissection (labetalol)
• Hyperthyroidism-induced hypertension
• Hypertension during pregnancy (labetalol is drug of choice)

B. Alpha-1 Adrenoceptor Blockers

• First-dose phenomenon: Severe orthostatic hypotension and syncope after first dose (especially prazosin) - give at bedtime with low initial dose
• Reflex tachycardia
• Fluid retention (use with diuretic)
• Nasal stuffiness

C. Central Sympatholytics

• Mechanism: Stimulates α2 receptors (and imidazoline receptors) in the brainstem vasomotor centers → ↓ sympathetic outflow → ↓ HR and BP; retains baroreceptor sensitivity
• Uses: Hypertension (oral); hypertensive urgency (oral/TTS patch); opioid/alcohol withdrawal; ADHD
• Adverse Effects: Sedation, dry mouth, bradycardia, depression
• Critical: Abrupt withdrawal causes rebound hypertension (sometimes severe - hypertensive crisis) - taper slowly

• Mechanism: Prodrug → α-methyldopamine → α-methylnorepinephrine (false transmitter) → stimulates central α2 receptors → ↓ sympathetic outflow
• Uses: Drug of choice for hypertension in pregnancy (proven safety record); also used in elderly
• Adverse Effects: Sedation, dry mouth, positive Coombs test (hemolytic anemia in ~1%), hepatotoxicity, drug fever, retroperitoneal fibrosis (rare)

---

V. Direct Vasodilators

Hydralazine

• Mechanism: Direct arteriolar smooth muscle relaxation (exact mechanism unclear; may involve NO release and inhibition of inositol trisphosphate-induced Ca²⁺ release)
• Dilates arterioles >> venules → ↓ peripheral resistance
• Uses: Moderate-severe hypertension (usually with β-blocker + diuretic); hypertension in pregnancy (IV for hypertensive emergencies); heart failure (hydralazine + nitrate combination)
• Adverse Effects:
  • Reflex tachycardia (must combine with β-blocker)
  • Fluid retention (combine with diuretic)
  • Drug-induced SLE (lupus-like syndrome) - dose-related; more in slow acetylators; presents with joint pains, rash, pleuritis
  • Headache, flushing, palpitations

Minoxidil

• Mechanism: Opens K⁺-ATP channels in vascular smooth muscle → hyperpolarization → Ca²⁺ channel closure → relaxation → vasodilation
• Most powerful oral vasodilator available
• Uses: Severe, refractory hypertension unresponsive to other agents
• Adverse Effects:
  • Hypertrichosis (hirsutism) - abnormal hair growth (basis for topical use as Rogaine® for baldness)
  • Severe fluid retention and edema (requires loop diuretic)
  • Reflex tachycardia (requires β-blocker)
  • Pericardial effusion (with prolonged use)

Sodium Nitroprusside (IV only)

• Mechanism: Releases NO (nitric oxide) → activates guanylyl cyclase → ↑ cGMP → vascular smooth muscle relaxation → dilates both arteries and veins
• Uses: Hypertensive emergencies (ICU only); aortic dissection; acute heart failure
• Adverse Effects: Cyanide toxicity (nitroprusside metabolized to cyanide) - limit duration; give thiosulfate to prevent; tachycardia, hypotension

Diazoxide (IV)

• Opens K⁺-ATP channels (similar to minoxidil) → arteriolar dilation
• Also inhibits insulin secretion → hyperglycemia
• Used in hypertensive emergencies

---

VI. Comparative Summary Table

---

VII. Drug Choice in Special Situations

---

VIII. Treatment Principles

1. BP target: <130/80 mmHg (AHA/ACC 2017); <140/90 mmHg (many other guidelines)
2. Lifestyle modifications first: sodium restriction, weight loss, exercise, alcohol reduction, DASH diet
3. First-line drug classes: ACEIs/ARBs, CCBs, thiazide diuretics (all equivalent for most patients without compelling indications)
4. Combination therapy: Most patients with stage 2 HTN (>160/100) require 2 or more drugs from different classes
5. Do NOT combine: ACEI + ARB (dual RAAS blockade increases harm)
6. Once-daily dosing preferred for compliance (trough-peak ratio >50%)
7. Blood pressure lowering itself is the most important therapeutic goal - no one class is clearly superior when BP is equivalently reduced

---

Megaloblastic Anemia - Pathology

Definition

---

Etiology and Classification

---

Biochemical Pathogenesis

The Core Problem: DNA Synthesis Failure

Normal Pathway

FOOD (B12-containing)
        ↓ [Pepsin releases B12]
B12 + Salivary haptocorrin
        ↓ [Pancreatic proteases in duodenum release B12 from haptocorrin]
B12 + INTRINSIC FACTOR (from gastric parietal cells)
        ↓ [B12-IF complex binds CUBILIN receptor in terminal ileum]
B12 absorbed → binds TRANSCOBALAMIN II in ileal cells
        ↓ [Delivered to liver and bone marrow]
METHYLCOBALAMIN (active B12)
        ↓ [cofactor for METHIONINE SYNTHASE]
N5-methyl FH4 → FH4 (tetrahydrofolate - active folate)
                    ↓
        N5,10-methylene FH4 (via FH4 derivatives)
                    ↓ [Thymidylate synthetase]
        dUMP → dTMP (deoxythymidine monophosphate)
                    ↓
              DNA SYNTHESIS

In B12 Deficiency: "Folate Trap"

↓ Methylcobalamin → Methionine synthase BLOCKED
        ↓
N5-methyl FH4 CANNOT be converted to FH4
        ↓
Folate is TRAPPED as N5-methyl FH4
        ↓
↓ FH4 → ↓ N5,10-methylene FH4
        ↓
Thymidylate synthetase STARVED of substrate
        ↓
↓ dTMP → ↓ DNA synthesis → MEGALOBLASTOSIS

"Folate trap hypothesis" - in B12 deficiency, folate accumulates in a form the cell cannot use, functionally mimicking folate deficiency. This explains why folate administration partially corrects the anemia of B12 deficiency but NOT the neurological complications.

Two Reactions Requiring B12

Critical distinction: The neurological damage from B12 deficiency is NOT corrected by folate (and may be worsened). Folate supplementation without B12 can mask hematological findings while neuropathy progresses unchecked.

In Folate Deficiency

↓ Dietary folate (or impaired absorption/increased demand)
        ↓
↓ FH4 → ↓ N5,10-methylene FH4
        ↓
↓ dTMP → ↓ DNA synthesis → MEGALOBLASTOSIS
        ↓
No neurological complications (folate not needed for myelin)

---

Morphology

1. Peripheral Blood Smear

2. Bone Marrow (Aspirate)

The key paradox: Bone marrow is hyperactive (hypercellular) yet peripheral blood counts are low (pancytopenia). This is the hallmark of ineffective hematopoiesis.

3. Hemolysis

• A mild degree of intramedullary and peripheral hemolysis compounds the anemia
• Mechanism: the fragile, abnormal megaloblasts are destroyed by macrophages in the marrow and spleen before they can mature
• Results in ↑ unconjugated bilirubin, ↑ LDH (very high), ↓ haptoglobin

---

Pernicious Anemia (Specific B12 Deficiency Subtype)

Autoimmune Pathogenesis

Autoreactive T cells attack gastric parietal cells
        ↓
Chronic atrophic gastritis (fundic gland atrophy)
        ↓
Loss of parietal cells → loss of intrinsic factor + HCl
        ↓
Three types of autoantibodies:
  Type I (75%) - blocks B12 binding to IF
  Type II (large proportion) - blocks IF-B12 complex from binding cubilin
  Type III (85-90%) - against α/β subunits of gastric proton pump (H+/K+ ATPase)
        ↓
↓ IF → B12 not absorbed from terminal ileum
        ↓
Gradual depletion of hepatic B12 stores (takes years - stores last 3-5 years)
        ↓
Megaloblastic anemia + Subacute combined degeneration

Morphology of Gastric Lesion

• Diffuse chronic atrophic gastritis of the fundus/body
• Loss of parietal cells (which secrete IF and HCl) and chief cells
• Replacement by mucus-secreting goblet cells: intestinal metaplasia (intestinalization)
• Megaloblastic changes in mucosal epithelial cells
• Dense lymphocyte and plasma cell infiltrate in lamina propria
• Important: Gastric changes persist after B12 replacement; marrow changes reverse rapidly

Neurological Lesion: Subacute Combined Degeneration (SCD)

• Seen in ~75% of florid pernicious anemia cases
• Mechanism: ↑ methylmalonyl-CoA → abnormal fatty acid synthesis → incorporated into neuronal lipids → myelin breakdown
• Pathology: Demyelination of posterior (dorsal) and lateral columns of spinal cord
• Clinical:
  • Posterior column: sensory ataxia, loss of vibration and proprioception, positive Romberg sign
  • Lateral column (corticospinal tracts): spastic paraparesis, extensor plantars
  • Peripheral neuropathy: symmetric distal paresthesias ("glove and stocking")
  • Cognitive changes, dementia, optic neuropathy
• Critical: Neurological damage may be IRREVERSIBLE if untreated; duration and severity before treatment inversely correlates with recovery

---

Clinical Features

Hematological

• Insidious onset; often severe anemia before diagnosis
• Pallor, fatigue, weakness, dyspnea
• Mild jaundice (from intramedullary hemolysis)
• Palpitations, heart failure in severe cases

Gastrointestinal

• Atrophic glossitis: tongue becomes smooth, shiny, "beefy red" with loss of papillae (Hunter's glossitis)
• Anorexia, nausea, weight loss
• Diarrhea from megaloblastic changes in intestinal epithelium

Neurological (B12 deficiency only, NOT folate)

• Bilateral symmetric distal paresthesias (tingling, numbness - earliest symptom)
• Loss of vibration sense and proprioception (posterior column dysfunction)
• Unsteady gait, sensory ataxia
• Spastic paraparesis, extensor plantars (lateral column)
• Lhermitte's sign (electric shock sensation down spine on neck flexion)
• Cognitive impairment, dementia, behavioral changes
• Neuropsychiatric manifestations can precede anemia

---

Laboratory Diagnosis

Distinguishing B12 from Folate Deficiency

---

Treatment